Topic Hub

Dapagliflozin — Regulatory History

4 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.

4articles

31keywords mapped

2026-05-26latest review

Explore

Dapagliflozin — Regulatory History library

Showing 4 of 4 clinical reviews.

Clinical Reviews2026-05-26

Farxiga (Dapagliflozin) Compounding Legal Status: FDA Approval, Label Details, and Regulatory Facts

Is compounding Farxiga (dapagliflozin) legal? Review FDA approval history, current label indications, patent status, compounding pharmacy regulations, and safety data for this SGLT2 inhibitor.

Read clinical review

Safety2026-05-27

Farxiga (Dapagliflozin) FAERS Safety Signals: Post-Market Surveillance Data

A clinical review of dapagliflozin (Farxiga) safety signals reported to the FDA Adverse Event Reporting System (FAERS), including DKA, Fournier gangrene, UTI, and volume depletion findings from post-market surveillance.

Read clinical review

Safety2026-05-25

Farxiga (Dapagliflozin) FDA Approval History: Every Indication, Label Change, and Safety Update

Complete timeline of Farxiga (dapagliflozin) FDA approvals, label expansions, boxed warning removals, and post-market safety communications from 2014 through 2025.

Read clinical review

Clinical Reviews2026-05-26

Farxiga Label Updates 2020 to 2026: A Complete FDA Regulatory Timeline for Dapagliflozin

Every FDA label change for Farxiga (dapagliflozin) from 2020 through 2026, including new indications for heart failure and CKD, safety warnings, and post-market surveillance findings.

Read clinical review